Company performance
Add to research
Current Price
as of Mar 14, 2025$2.03
P/E Ratio
N/A
Market Cap
$73.28M
- FLL
Description
Add to research
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
Metrics
Add to research
Overview
- HQPlymouth Meeting, PA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerINO
- Price$2.03+5.18%
Trading Information
- Market cap$73.28M
- Float99.31%
- Average Daily Volume (1m)634,600
- Average Daily Volume (3m)873,335
- EPS-$4.48
Company
- Revenue$0.20M
- Rev growth (1yr)-100.00%
- Net income-$25.17M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$26.58M
- EV$90.29M
- EV/Revenue443.89
- P/EN/A
- P/S280.83
- P/B0.72
- Debt/Equity16.92
Documents
Add to research
SEC Filings
Earnings Calls